LES TUMEURS NEUROENDOCRINES DIGESTIVES : RECLASSEMENT DE 26 CAS SELON LA CLASSIFICATION DE L’OMS 2010
Mots-clés :
Tumeur, neuroendocrine, classification, Ki-67Résumé
Problématique : L’hétérogénéité et la rareté des tumeurs neuroendocrines digestives rendent leur classification difficile.Objectif du travail : Reclasser les tumeurs neuroendocrines selon la dernière classification de l’OMS 2010.
Méthodes : Une étude rétrospective portant sur 26 patients porteurs de tumeurs neuroendocrines digestives colligés au Laboratoire d’Anatomie et de Cytologie Pathologique de l’Hôpital Militaire de Tunis de 2000 à 2013.
Résultats : L’âge moyen des patients était de 49,64 ans. Le sex-ratio était de 1,36. Il s’agissait 6 tumeurs gastriques, 5 tumeurs de l’intestin grêle, 5 tumeurs du pancréas, 5 tumeurs de l’appendice, une tumeur hépatique, une tumeur de la vésicule biliaire, une tumeur rectale et une tumeur colique. Selon la classification de l’OMS 2000, les tumeurs sont réparties en 11 tumeurs endocrines bien différenciées, 13 carcinomes endocrines bien différenciés et deux carcinomes peu différenciés. Selon la classification de l’OMS 2010, les tumeurs sont réparties en 16 de tumeurs neuroendocrines grade 1, 6 tumeurs neuroendocrines grade 2, 4 carcinomes neuroendocrines.
Conclusion : Il existait une concordance entre les deux classifications dans 93 % des cas. La classification de l’OMS 2010 permet de mieux classer les tumeurs neuroendocrines digestives, avec cependant la présence de quelques formes histologiques qui restaient difficilement classables.
Téléchargements
Références
Walter T, Scoazec J-Y, Lepage C. Épidémiologie des tumeurs neuroendocrines digestives: la situation en France. Hépato-gastro & oncologie digestive. 2013; 20(3): 160-6.
World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer, 2010.
Scarpa A, Mantovani W, Capelli P, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 2010; 23(6): 824-33.
Saint-André J-P. Système des cellules neuroendocrines. Endocrinologie - Nutrition. 2000; 10(1): 1-8.
Klöppel G, Rindi G, Anlauf M, Perren A, Komminoth P. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch. 2007; 451 (Suppl 1): S9-27.
Niederle MB, Niederle B. Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation. Oncologist. 2011;16(5): 602-13.
Turaga KK, Kvols LK. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2011; 61(2): 113-32.
Alsina M, Marcos-Gragera R, Capdevila J, et al. Neuroendocrine tumors: a population-based study of incidence and survival in Girona Province, 1994- 2004. Cancer Epidemiol. 2011; 35(6): 49-54.
Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008; 113(10): 2655-64.
Auernhammer CJ, Göke B. Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut. 2011; 60(7): 1009-21.
Frilling A, Akerström G, Falconi M, et al. Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer. 2012; 19(5): 163-85.
Yao JC, Hassan M, Phan A, et al. One hundred years after « carcinoid »: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18): 3063-72.
Lepage C, Ciccolallo L, De Angelis R, et al. European disparities in malignant digestive endocrine tumours survival. Int J Cancer. 2010; 126(12): 2928-34.
Ben Ameur H. Les tumeurs endocrines digestives: Résultats d'une étude multicentrique tunisienne. Médecine du Maghreb. 2013; 212: 19-29.
R Rjiba. Les tumeurs endocrines digestives: aspects cliniques et modalités thérapeutiques, à propos de neuf cas. La tunisie Medicale. 2011; 89(01):103.
Calender A. Néoplasie endocrinienne multiple de type 1 : aspects génétiques et cliniques. Gastroentérologie Clinique et Biologique. 2001; 25(4): 38.
Baudin E. Gastroenteropancreatic endocrine tumors: clinical characterization before therapy. Nat Clin Pract Endocrinol Metab. 2007; 3(3): 228-39.
Habal N, Sims C, Bilchik AJ. Gastrointestinal carcinoid tumors and second primary malignancies. J Surg Oncol. 2000; 75(4): 310-6.
Calzada M, Keller I, Potier L, et al. Médecine nucléaire et imagerie multimodalités des tumeurs endocrines. Médecine Nucléaire. 2010; 34(8): 444-50.
Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005; 128(6): 1717-51.
Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocrine RelatedCancer. 2010; 17(4): 909-18.
Pape U-F, Jann H, Müller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008; 113(2): 256-65.
Klöppel G. Oberndorfer and his successors: from carcinoid to neuroendocrine carcinoma. Endocr Pathol. 2007; 18(3): 141-4.
Capelli P, Fassan M, Scarpa A. Pathology - grading and staging of GEPNETs. Best Pract Res Clin Gastroenterol. 2012; 26(6): 705-17.
Strosberg JR, Nasir A, Hodul P, Kvols L. Biology and Treatment of Metastatic Gastrointestinal Neuroendocrine Tumors. Gastrointest Cancer Res. 2008; 2(3): 113-25.
Ozkara S, Aker F, Yesil A, et al. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria. Hepatogastroenterology. 2013; 60(127): 1665-72.
Scoazec J-Y. Tumeurs endocrines : biologie et physiopathologie. Annales de pathologie. 2005; 25(6): 447-61.
Tang LH. High grade transformation of differentiated neuroendocrine neoplasms (NENs) of the enteropancreatic system - A unique entity distinct from de novo high grade neuroendocrine carcinoma (HGNECa) in pathogenesis and clinical behavior. Laboratory Investigation. 2008; 88(Suppl.1): 137A.
Vélayoudom-Céphise F-L, Duvillard P, Foucan L, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer. 2013; 20(5): 649-57.
Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012; 36(2): 173-84.
Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005; 12(4): 1083-92.
Larghi A, Capurso G, Carnuccio A, et al. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUSguided fine-needle tissue acquisition: a prospective study. Gastrointest Endosc. 2012; 76(3): 570-7.
Francesco Panzuto LB. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011; 29(17): 2372-7.
Bettini R, Boninsegna L, Mantovani W, et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol. 2008; 19(5):903-8.
